Frequency of revaccination against smallpox.
Recent suggestions to revise guidelines that recommend extending the time for revaccination re·vac·ci·na·tion
Vaccination of a person previously vaccinated. beyond 10 years may be based on insufficient and conflicting evidence of persistence of immunity (1,2). The evidence that cell-mediated immunity cell-mediated immunity
n. Abbr. CMI
Immunity resulting from a cell-mediated immune response. Also called cellular immunity. and neutralizing antibody neu·tral·iz·ing antibody
An antibody that reacts with an infectious agent, usually a virus, and destroys or inhibits its infectiveness and virulence. persist after one vaccination is conflicting (2-5). This residual immunity is often low, and its protective activity in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body.
Within a living organism.
in vivo adv. is unclear. Similarly, in vivo reports of durable immunity to smallpox (1) were not sufficiently controlled, and short persistence of resistance to dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin.
der·mal or der·mic
Of or relating to the skin or dermis. challenge with the antigenically related vaccinia virus has been reported (3,6).
We confirmed the previous report (5) that the residual antivaccinia virus titers of serum samples from singly vaccinated adults are low (average 32) (Table). The titer of normal commercial immunoglobulin (Ig) (Panglobulin) (11 times concentrated sera) was 150 U/mL, which when calculated to include the 11-fold concentration, confirms the low residual titers.
The titers of the control, unvaccinated persons, averaged 14, raising questions about the importance and specificity of the residual antibody in vaccinated persons. We determined that the persistent neutralizing activity is mainly IgG antibody in serum from both single-vaccinated persons and ordinary commercial IgG, since sequential absorption with protein G beads and anti-IgG beads reduced the titers 80%. However, the neutralizing activity in unvaccinated control serum may not be mainly IgG antibody since neutralizing activity was reduced by an average of 48%, favoring nonspecific nonspecific /non·spe·cif·ic/ (non?spi-sif´ik)
1. not due to any single known cause.
2. not directed against a particular agent, but rather having a general effect.
1. inhibitors. Studies of these nonspecific inhibitors and possible cross-immunizing antigens in the environment should be conducted to explain the occurrence of neutralizing activity in serum of unvaccinated persons.
To determine whether the low residual titers in sera from single vaccinated persons protected in vivo against a systemic infection, mice were pretreated subcutaneously with 1 mL of either 1) serum from a single-vaccinated study participant containing the low 10 U/mL neutralizing activity (patient A), 2) serum from a single-vaccinated person containing the higher 43 U/mL (patient E), or 3) normal commercial Ig containing 150 U/mL and challenged 24 hours later with one L[D.sub.100] vaccinia virus, strain IHD-E, intraperitoneally. The 1 mL of serum injected into the mice is estimated to provide its original titer in the mouse. The lowest titer serum (10 U/mL) did not protect the mice against lethal systemic infection, whereas the highest titer serum (43 U/mL) and the commercial Ig (150 U/mL) protected 50% of the mice. Thus, the levels of residual antibody in vaccinated persons are either not protective or only partially protective in mice. Consistent with the reported protection by the higher levels of antibody, vaccinia vac·cin·i·a
1. See cowpox.
2. An infection induced in humans by inoculation with the vaccinia virus in order to confer resistance to smallpox; it is usually limited to the site of inoculation. immune globulin (VIG VIG Vaccine Immune Globulin
VIG Video Interface Group (Navy)
VIG Vision Interface Group (Massachusetts Institute of Technology)
VIG Video Gateway
VIG Vpn Internet Gateway ), which contains 500 neutralizing U/mL, is effective under some conditions (7-10). As a positive control for protection in this animal model, 100 [micro]g of the interferon inducer inducer /in·duc·er/ (in-dldbomacs´er) a molecule that causes a cell or organism to accelerate synthesis of an enzyme or sequence of enzymes in response to a developmental signal.
n. Poly I:CLC (The Computer Language Company Inc.) The publisher of this Encyclopedia. See About this product. protected 100% of the mice. Undetermined and requiring study is whether active immunity might be protective through an anamnestic response. The animal models of poxvirus poxvirus
Any of a group of viruses responsible for a wide range of pox diseases in humans and other animals. Poxvirus was the cause of smallpox. (Human chickenpox is caused by varicella-zoster virus. infection have been used to evaluate immunity, but no generally established laboratory surrogate exists for immunity to smallpox virus itself. Persistence of effective humoral immunity alter a single vaccination and its ability to effectively protect in vivo remain questionable.
Table. Residual vaccinia virus neutralizing titers of a serum from vaccinated and unvaccinated persons Y after Neutralizing Participant no. vaccination titer Single-vaccinated persons A 47 10 B 50 26 C 45 27 D 40 34 E 40 43 Ordinary commercial 150 immunoglobulin (Panglobulin) Unvaccinated persons H6 -- (a) <10 H9 -- <10 C2 -- <10 C4 -- <10 H1 -- 10 H2 -- 10 H13 -- 10 C1 -- 10 C3 -- 10 H7 -- 10 HL -- 20 H3 -- 20 H4 -- 20 H5 -- 20 H10 -- 20 Hll -- 20 H12 -- 20 C7 -- 20 H8 -- 30 (a) --, Not applicable.
We thank Tasnee Chonmaitree and David Hudnall for providing serum samples.
Dr. Baron is a professor in the Department of Microbiology and Immunology and the Department of Internal Medicine at the University of Texas Medical Branch "UTMB" redirects here. For other system schools, see University of Texas System.
The University of Texas Medical Branch (UTMB) is a component of the University of Texas System located in Galveston, Texas, about 50 miles (80 km) southeast of downtown Houston. at Galveston. He conducts research on the pathogenesis of virus infections and host defenses, including interferon, immunity, smallpox, HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , and respiratory viruses.
(1.) Cohen cohen
(Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. J. Smallpox vaccinations: how much protection remains? Science 2001;294:985.
(2.) Frelinger JA, Garba ML. Responses to smallpox vaccine. N Engl J Med 2002;347:689-90.
(3.) Moller-Larsen A, Haahr S. Humoral hu·mor·al
1. Relating to body fluids, especially serum.
2. Relating to or arising from any of the bodily humors.
Pertaining to or derived from a body fluid. and cell-mediated immune responses in humans before and after revaccination with vaccinia virus. Infect Immun 1978;19:34-9.
(4.) Demkowicz WE, Jr., Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996;70:2627-31.
(5.) Stienlauf S, Shoresh M, Solomon A, Lublin-Tennenbaum T. Atsmon Y, Meirovich, et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 1999;17:201-4.
(6.) Speers WC, Wesley RB, Neff JM, Goldstein J, Lourie lourie or loerie
a type of African bird with either crimson or grey plumage [Afrikaans, from Malay] B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic se·rol·o·gy
n. pl. se·rol·o·gies
1. The science that deals with the properties and reactions of serums, especially blood serum.
2. observations of response to revaccination with calf lymph vaccine. Pediatr Res 1975:9:628-32.
(7.) Douglas RG, Lynch; EC, Spira M. Treatment of progressive vaccinia. Arch Intern Med 1972;129:980-3.
(8.) Kesson AM. Ferguson J K, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin ribavirin /ri·ba·vi·rin/ (ri?bah-vi´rin) a broad-spectrum antiviral used in the treatment of severe viral pneumonia caused by respiratory syncytial virus, particularly in high-risk infants; also used in conjunction with interferon and vaccinia immune globulin. Clin Infect Dis 1997;25:911-4.
(9.) Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975;55:342-7.
(10.) Feery BJ. Adverse reactions after smallpox vaccination. Med J Aust 1977;2:180-3.
Address for correspondence: Samuel Baron, University of Texas Medical Branch, Department of Microbiology mad Immunology, 301 University Boulevard, Galveston, TX 77555-1019, USA; fax: (409) 772-2325; email: email@example.com
Samuel Baron, * Jingzhi Pan, * and Joyce Poast *
* University of Texas Medical Branch, Galveston, Texas, USA